180 related articles for article (PubMed ID: 31782368)
1. Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.
Benko Z; Zhang J; Zhao RY
Curr HIV Res; 2019; 17(6):429-440. PubMed ID: 31782368
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Protease in the Fission Yeast Schizosaccharomyces pombe.
Benko Z; Elder RT; Li G; Liang D; Zhao RY
PLoS One; 2016; 11(3):e0151286. PubMed ID: 26982200
[TBL] [Abstract][Full Text] [Related]
3. Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (
Zhang J; Vernon K; Li Q; Benko Z; Amoroso A; Nasr M; Zhao RY
Pathogens; 2021 Jun; 10(7):. PubMed ID: 34202872
[TBL] [Abstract][Full Text] [Related]
4. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.
Fuse T; Watanabe K; Kitazato K; Kobayashi N
Microbes Infect; 2006 Jun; 8(7):1783-9. PubMed ID: 16815068
[TBL] [Abstract][Full Text] [Related]
6. A drug discovery platform: a simplified immunoassay for analyzing HIV protease activity.
Kitidee K; Nangola S; Hadpech S; Laopajon W; Kasinrerk W; Tayapiwatana C
J Virol Methods; 2012 Dec; 186(1-2):21-9. PubMed ID: 22846787
[TBL] [Abstract][Full Text] [Related]
7. A fission yeast cell-based system for multidrug resistant HIV-1 proteases.
Benko Z; Liang D; Li G; Elder RT; Sarkar A; Takayama J; Ghosh AK; Zhao RY
Cell Biosci; 2017; 7():5. PubMed ID: 28096973
[TBL] [Abstract][Full Text] [Related]
8. Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs.
Cheng N; Lee SK; Donover PS; Reichman M; Schiffer CA; Hull-Ryde EA; Swanstrom R; Janzen WP
J Lab Autom; 2014 Jun; 19(3):297-303. PubMed ID: 24305957
[TBL] [Abstract][Full Text] [Related]
9. Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment.
Huang L; Li L; Tien C; LaBarbera DV; Chen C
Sci Rep; 2019 Jan; 9(1):301. PubMed ID: 30670786
[TBL] [Abstract][Full Text] [Related]
10. A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.
Buzon MJ; Erkizia I; Pou C; Minuesa G; Puertas MC; Esteve A; Castello A; Santos JR; Prado JG; Izquierdo-Useros N; Pattery T; Van Houtte M; Carrasco L; Clotet B; Ruiz L; Martinez-Picado J
J Antimicrob Chemother; 2012 Jan; 67(1):32-8. PubMed ID: 21994909
[TBL] [Abstract][Full Text] [Related]
11. Yeast cells as a tool for analysis of HIV-1 protease susceptibility to protease inhibitors, a comparative study.
Ravaux I; Perrin-East C; Attias C; Cottalorda J; Durant J; Dellamonica P; Gluschankof P; Stein A; Tamalet C
J Virol Methods; 2014 Jan; 195():180-4. PubMed ID: 24056262
[TBL] [Abstract][Full Text] [Related]
12. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
[TBL] [Abstract][Full Text] [Related]
13. Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.
Yang H; Nkeze J; Zhao RY
Cell Biosci; 2012 Sep; 2(1):32. PubMed ID: 22971934
[TBL] [Abstract][Full Text] [Related]
14. Novel Protease Inhibitors Containing C-5-Modified
Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
[TBL] [Abstract][Full Text] [Related]
15. An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells.
Hilton BJ; Wolkowicz R
PLoS One; 2010 Jun; 5(6):e10940. PubMed ID: 20532177
[TBL] [Abstract][Full Text] [Related]
16. A chemical compound for controlled expression of nmt1-driven gene in the fission yeast Schizosaccharomyces pombe.
Nakamura Y; Arai A; Takebe Y; Masuda M
Anal Biochem; 2011 May; 412(2):159-64. PubMed ID: 21295003
[TBL] [Abstract][Full Text] [Related]
17. Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.
Lin YC; Happer M; Elder JH
J Virol; 2013 Aug; 87(15):8524-34. PubMed ID: 23720716
[TBL] [Abstract][Full Text] [Related]
18. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
[TBL] [Abstract][Full Text] [Related]
20. Exploring the energetic basis of binding of currently used drugs against HIV-1 subtype CRF01_AE protease via molecular dynamics simulations.
Sk MF; Jonniya NA; Kar P
J Biomol Struct Dyn; 2021 Oct; 39(16):5892-5909. PubMed ID: 32696717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
